Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions

Oncogene

Volumn 28, Issue 48, 2009, Pages 4284-4294

  Walerych, D ^a   Olszewski, M B ^a   Gutkowska, M ^a,b   Helwak, A ^a,c   Zylicz, M ^a   Zylicz, A ^a  

^a INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^c INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

Hsp70; Hsp90; P53; molecular chaperones; Protein folding

Indexed keywords

HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN P53;

ARTICLE; CANCER INHIBITION; DNA BINDING; HEAT SHOCK; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; TEMPERATURE; WILD TYPE;

BINDING SITES; HEAT-SHOCK RESPONSE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEIN FOLDING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 71349086944     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.281     Document Type: Article

References (47)

1. Agashe VR, Hartl FU. (2000). Roles of molecular chaperones in cytoplasmic protein folding. Semin Cell Dev Biol 11: 15-25.
2. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM. (2006). Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 281: 2989-2998.
3. Bell S, Klein C, Muller L, Hansen S, Buchner J. (2002). p53 contains large unstructured regions in its native state. J Mol Biol 322: 917-927.
4. Bullock AN, Henckel J, Fersht AR. (2000). Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245-1256.
5. Butler JS, Loh SN. (2006). Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature. Protein Sci 15: 2457-2465.
6. Canadillas JM, Tidow H, Freund SM, Rutherford TJ, Ang HC, Fersht AR. (2006). Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci USA 103: 2109-2114.
7. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumori-genic mutations. Science 265: 346-355.
8. Daugaard M, Rohde M, Jaattela M. (2007). The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. FEBS Lett 581: 3702-3710.
9. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW et al. (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28: 289-298.
10. Fourie AM, Hupp TR, Lane DP, Sang BC, Barbosa MS, Sambrook JF et al. (1997). HSP70 binding sites in the tumor suppressor protein p53. J Biol Chem 272: 19471-19479.
11. Freeman BC, Morimoto RI. (1996). The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. EMBO J 15: 2969-2979.
12. Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR. (2004). Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for 'mutant conformation'. J Mol Biol 336: 187-196.
13. Hansen S, Hupp TR, Lane DP. (1996). Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. J Biol Chem 271: 3917-3924.
14. Hernandez MP, Sullivan WP, Toft DO. (2002). The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J Biol Chem 277: 38294-38304.
15. Hu J, Flores D, Toft D, Wang X, Nguyen D. (2004). Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol 78: 13122-13131.
16. Kaeser MD, Iggo RD. (2002). Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99: 95-100.
17. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
18. King FW, Wawrzynow A, Hohfeld J, Zylicz M. (2001). Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J 20: 6297-6305.
19. Klucken J, Shin Y, Hyman BT, McLean PJ. (2004). A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem Biophys Res Commun 325: 367-373.
20. Laptenko O, Prives C. (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13: 951-961.
21. Lee DW, Zhao X, Zhang F, Eisenberg E, Greene LE. (2005). Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors. J Cell Sci 118: 4311-4321.
22. Liberek K, Marszalek J, Ang D, Georgopoulos C, Zylicz M. (1991). Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc Natl Acad Sci USA 88: 2874-2878.
23. Milner J, Medcalf EA. (1990). Temperature-dependent switching between 'wild-type' and 'mutant' forms of p53-Val135. J Mol Biol 216: 481-484.
24. Morishima Y, Murphy PJ, Li DP, Sanchez ER, Pratt WB. (2000). Stepwise assembly of a glucocorticoid receptor.hsp90 heterocom-plex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J Biol Chem 275: 18054-18060.
25. Muller L, Schaupp A, Walerych D, Wegele H, Buchner J. (2004). Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J Biol Chem 279: 48846-48854.
26. Muller P, Ceskova P, Vojtesek B. (2005). Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem 280: 6682-6691.
27. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. (2008). Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 27: 3371-3383.
28. Newmyer SL, Schmid SL. (2001). Dominant-interfering Hsc70 mutants disrupt multiple stages of the clathrin-coated vesicle cycle in vivo. J Cell Biol 152: 607-620.
29. Pacey S, Banerji U, Judson I, Workman P. (2006). In: Gaestel M (ed). Handbook on Experimental Pharmacology. Springer-Verlag: Berlin, Heidelberg, pp 331-358.
30. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
31. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, Oren M. (1986). Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320: 182-184.
32. Rudiger S, Freund SM, Veprintsev DB, Fersht AR. (2002). CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci USA 99: 11085-11090.
33. Rutherford SL, Lindquist S. (1998). Hsp90 as a capacitor for morphological evolution. Nature 396: 336-342.
34. Sangster TA, Lindquist S, Queitsch C. (2004). Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays 26: 348-362.
35. Sasaki M, Nie L, Maki CG. (2007). MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem 282: 14626-14634.
36. Schulte TW, Neckers LM. (1998). The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279.
37. Selivanova G, Wiman KG. (2007). Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26: 2243-2254.
38. Sepehrnia B, Paz IB, Dasgupta G, Momand J. (1996). Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 271: 15084-15090.
39. Sreedhar AS, Kalmar E, Csermely P, Shen YF. (2004). Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562: 11-15.
40. Sugito K, Yamane M, Hattori H, Hayashi Y, Tohnai I, Ueda M et al. (1995). Interaction between hsp70 and hsp40, eukaryotic homo-logues of DnaK and DnaJ, in human cells expressing mutant-type p53. FEBS Lett 358: 161-164.
41. Vousden KH, Lane DP. (2007). p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
42. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW et al. (2004). Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279: 48836-48845.
43. Wang C, Chen J. (2003). Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J Biol Chem 278: 2066-2071.
44. Wegele H, Muller L, Buchner J. (2004). Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 151: 1-44.
45. Wells M, Tidow H, Rutherford TJ, Markwick P, Jensen MR, Mylonas E et al. (2008). Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci USA 105: 5762-5767.
46. Zylicz M, Ang D, Liberek K, Georgopoulos C. (1989). Initiation of lambda DNA replication with purified host-and bacteriophage-encoded proteins: the role of the dnaK, dnaJ and grpE heat shock proteins. EMBO J 8: 1601-1608.
47. Zylicz M, King FW, Wawrzynow A. (2001). Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 20: 4634-4638